Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Gore

Showing results (241-250 of 251) with videos related to

Pageof 26
Sort By:
BMJ Open Diabetes Research & Care|January 21, 2020
Genetic factors and risk of type 2 diabetes among women with a history of gestational diabetes: findings from two independent populationsMengying Li, Mohammad L Rahman, Jing Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2009
PPM1D is a potential therapeutic target in ovarian clear cell carcinomasDavid S P Tan, Maryou B K Lambros, Sydonia Rayter, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2014
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanomaSander Kelderman, Bianca Heemskerk, Harm van Tinteren, et al.
American Journal of Obstetrics and Gynecology|June 5, 2024
Multiethnic growth standards for fetal body composition and organ volumes derived from 3D ultrasonographyKatherine L Grantz, Wesley Lee, Lauren M Mack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional studyJoo Ern Ang, Charlie Gourley, C Bethan Powell, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
JAMA|January 26, 2012
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancerKelly L Bolton, Georgia Chenevix-Trench, Cindy Goh, et al.
Nature Genetics|August 4, 2009
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2Honglin Song, Susan J Ramus, Jonathan Tyrer, et al.
Nature Genetics|September 21, 2010
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24Ellen L Goode, Georgia Chenevix-Trench, Honglin Song, et al.
Pageof 26

Showing results (241-250 of 251) with videos related to

Sort By:
Pageof 26
BMJ Open Diabetes Research & Care|January 21, 2020
Genetic factors and risk of type 2 diabetes among women with a history of gestational diabetes: findings from two independent populationsMengying Li, Mohammad L Rahman, Jing Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2009
PPM1D is a potential therapeutic target in ovarian clear cell carcinomasDavid S P Tan, Maryou B K Lambros, Sydonia Rayter, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2014
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanomaSander Kelderman, Bianca Heemskerk, Harm van Tinteren, et al.
American Journal of Obstetrics and Gynecology|June 5, 2024
Multiethnic growth standards for fetal body composition and organ volumes derived from 3D ultrasonographyKatherine L Grantz, Wesley Lee, Lauren M Mack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional studyJoo Ern Ang, Charlie Gourley, C Bethan Powell, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
JAMA|January 26, 2012
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancerKelly L Bolton, Georgia Chenevix-Trench, Cindy Goh, et al.
Nature Genetics|August 4, 2009
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2Honglin Song, Susan J Ramus, Jonathan Tyrer, et al.
Nature Genetics|September 21, 2010
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24Ellen L Goode, Georgia Chenevix-Trench, Honglin Song, et al.
Pageof 26